-->
Alpharma To Withdraw And Resubmit Its New Drug Application For EMBEDA ( TM ) |
Alpharma To Withdraw And Resubmit Its New Drug Application For EMBEDA ( TM )Alpharma Inc. ( NYSE: ALO ) , a global specialty pharmaceutical company, announced that it has withdrawn its New Drug Application ( 'NDA' ) for EMBEDA™ ( morphine sulfate extended-release with sequestered naltrexone hydrochloride ) Capsules, and plans to resubmit a revised application as soon as possible. While the initial NDA submission qualified for a priority review, certain technical issues around data presentation prevented a complete evaluation by U. S. Food and Drug Administration ( " FDA' ) within six month time period permissible for a priority review. The Company expects to address submission issues and re-qualify for priority review in its resubmission. Alpharma is fully committed to collaborating with Food and Drug Administration to complete a timely review of EMBEDA™ NDA, and continues to anticipate a first quarter 2009 launch following approval. EMBEDA™ was developed with Alpharma's proprietary technology, which combines an extended release opioid with sequestered naltrexone, an opioid antagonist. In clinical trials, when EMBEDA™ was taken as directed, it provided effective pain relief and sequestered naltrexone passed through body without effect. When EMBEDA™ Capsule was crushed, chewed or dissolved, which are common approaches abusers use to tamper with product in order to gain euphoria, the naltrexone was released thereby significantly reducing euphoric effect of opioid. Statements made in this press release include forward-looking statements within meaning of the Private Securities Litigation Reform Act of 1995. These statements, including those relating to future financial expectations, involve certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. Information on other important potential risks and uncertainties not discussed herein may be found in Company's filings with the Securities and Exchange Commission including its Annual Report on Form 10-K for year ended December 31, 2007. About Alpharma Alpharma Inc. ( NYSE: ALO ) is a global specialty pharmaceutical company with leadership positions in products for humans and animals. Alpharma is presently active in more than 80 countries. Alpharma has a growing branded pharmaceutical franchise in U. S. pain market with its KADIAN� ( morphine sulfate extended-release ) Capsules, and FLECTOR� Patch ( diclofenac epolamine topical patch ) . Alpharma is also internationally recognized as a leading provider of pharmaceutical products for poultry and livestock. Alpharma Use abortion tablets |
Levitra benefits.Levitra: uses Levitra is used to treat male sexual function problems ( impotence or erectile dysfunction ) by blocking a certain enzyme ( phosphodiesterase-PDE5 ) . In combination with sexual stimulation, Levitra works by helping blood flow into penis to achieve and maintain an erection. Levitra: how to use Levitra is taken by mouth as needed, 1 hour before sexual activity with or without food; or use as directed by your doctor. Don't take more often than once daily as needed. Levitra: side effects Headache, flushing, nasal stuffiness, stomach upset, heartburn, runny nose, dizziness, or nausea may occur while use Levitra. Vision changes such as increased sensitivity to light, blurred vision, or impaired blue/green color discrimination may also occur. If any of these effects persist or worsen, notify your doctor or pharmacist promptly. Levitra: precautions Before taking Levitra, tell your doctor or pharmacist if we are allergic to it; or if you have any other allergies. Levitra: interactions Your doctor or pharmacist may already be aware of any possible drug interactions and may be monitoring we for them. Don't start, stop, or change the dosage of any medicine before checking with them first. Where to buy cheap Levitra |
Facts About Crohn's Disease. On January 14, 2008, FDA approved Tysabri (natalizumab) for certain patients with moderate-to-severe Crohn�s disease, a chronic inflammatory condition of the digestive tract. Here are facts about the symptoms and treatments for this condition. Food Label Helps Consumers Make Healthier Choices. The food label allows you to compare foods quickly and easily to choose the ones that best fit your dietary needs. New Safety Warnings for Chantix. FDA alerts the public and health care providers to mood and behavior changes associated with this medicine to help people quit smoking Living with Fibromyalgia, Drugs Approved to Manage Pain. A second drug has been approved to treat fibromyalgia, a painful chronic condition that affects the muscles and joints. |
Prostate Cancer Treatment Could Impair Men's Thinking. TUESDAY, July 29 -- Men undergoing hormonedeprivation therapy to keep prostate cancer at bay may experience memoryloss and have trouble concentrating, a new study finds. Thyroid Hormone May Boost Women's Alzheimer's Risk. TUESDAY, July 29 -- High or low levels of thehormone thyrotropin may be associated with an increased risk ofAlzheimer's disease in women. Thyrotropin affects thyroid gland functionand thyroid hormone levels. Clinical Trials Update: July 29, 2008. -- Here are the latest clinical trials, courtesyof CenterWatch:. Impotence drugs help treat brain tumors: study. Impotence drugs may help carry cancer-fighting drugs through the brain to treat malignant tumors, U.S. researchers reported on Monday. Obesity not a contraindication to knee replacement. Obese individuals with arthritic knees should not be denied knee replacement surgery, researchers conclude, based on a new study showing that obese patients benefit from the surgery almost as much as their normal-weight peers. Children target of $1.6 billion in food ads, FTC finds. Imagine Superman promoting fresh fruits and vegetables instead of a cereal. |
Alpharma To Withdraw And Resubmit Its New Drug Application For EMBEDA ( TM ) Levitra benefits. Where to buy cheap Levitra Facts About Crohn's Disease. On January 14, 2008, FDA approved Tysabri (natalizumab) for certain patients with moderate-to-severe Crohn�s disease, a chronic inflammatory condition of the digestive tract. Here are facts about the symptoms and treatments for this condition. Use abortion tablets |